Oncolytics Biotech Inc Announces US Phase II Clinical Trial for Advanced Pancreatic Cancer

Strategic Insights -

Researchers at the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio have begun enrolling patients in a US Phase II clinical trial using a novel combination of Reolysin and gemcitabine to treat advanced pancreatic cancer. This study aims to determine the clinical benefit rate, progression-free survival, and safety of this treatment combination in patients with measurable disease. Led by Principal Investigator Dr. Monica Mita, the trial is expected to enroll up to 33 patients and will provide valuable insights into the potential of oncolytic viruses as cancer therapeutics.

Key Takeaways:

  • The CTRC has started patient enrolment in a US Phase II clinical trial for advanced pancreatic cancer using Reolysin and gemcitabine.
  • The trial is a single arm, open-label, Phase II study with a primary objective of determining the clinical benefit rate of Reolysin in combination with gemcitabine.
  • The trial will enroll up to 33 patients with advanced or metastatic pancreatic cancer and has a secondary objective of determining the safety and tolerability of Reolysin with gemcitabine.
  • This trial is part of a broad pre-clinical and clinical collaboration between Oncolytics Biotech Inc and the CTRC, exploring the use of Reolysin in combination with chemotherapy for various cancer indications.
  • The combination of Reolysin and gemcitabine has shown promise in pre-clinical studies, with potential to improve clinical outcomes for patients with advanced pancreatic cancer.
  • Dr. Monica Mita is the Principal Investigator of the trial, and Oncolytics Biotech Inc is a Calgary-based biotechnology company focused on the development of oncolytic viruses as cancer therapeutics.

Statistics:

  • The trial aims to enroll up to 33 patients with advanced or metastatic pancreatic cancer.
  • The trial is designed as a single arm, open-label, Phase II study.
  • The primary objective of the trial is to determine the clinical benefit rate (complete response (CR) + partial response (PR) + stable disease (SD)) of Reolysin and gemcitabine in patients with advanced or metastatic pancreatic cancer.
  • The secondary objectives are to determine the progression-free survival and to determine the safety and tolerability of Reolysin and gemcitabine.

Sources:

  • Oncolytics Biotech Inc
  • Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC)
  • Dr. Monica Mita of the CTRC